Rezurock (belumosudil) is a medicine indicated for the treatment of chronic graft-versus-host disease (cGVHD) in adults and adolescents aged 12 years and older weighing at least 40 kg after hematopoietic cell transplantation when other treatments have failed or are not suitable.[2] It contains the active substance belumosudil, which blocks the ROCK2 protein involved in immune reactions in cGVHD and protects organs from attack by donor cells.[2] The European Medicines Agency (EMA) issued an opinion on the registration application, but the company is unable to provide further efficacy data until April 2030, so conditional registration was not granted.[2] Rezurock has orphan drug designation for a rare disease since October 17, 2019 and is available as a pill.[2] In the US, it has FDA registration for the same use in patients 12 years of age and older.[4] In an economic analysis, belumosudil demonstrated cost-effectiveness over standard treatment in patients with at least two prior lines of therapy, with a gain of 0.854 QALYs at a willingness-to-pay of £30,000 per QALY.[1] Cost savings for side effects and healthcare resources are expected to be approximately $173.5 million in 2026 from a US payer perspective.[1]